Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 45,400 shares, a growth of 6.3% from the May 31st total of 42,700 shares. Based on an average daily volume of 45,900 shares, the short-interest ratio is presently 1.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Beacon Capital Management LLC increased its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 606.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 48,633 shares of the company’s stock after acquiring an additional 41,752 shares during the quarter. Beacon Capital Management LLC owned about 0.17% of Evaxion Biotech A/S worth $33,000 at the end of the most recent quarter. Institutional investors own 11.04% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on EVAX shares. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a report on Tuesday, June 4th. LADENBURG THALM/SH SH raised shares of Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a report on Tuesday, April 2nd.

Evaxion Biotech A/S Stock Performance

EVAX opened at $2.90 on Wednesday. The firm’s fifty day moving average is $3.51 and its 200 day moving average is $4.41. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.82.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Tuesday, May 28th. The company reported $0.03 EPS for the quarter. The business had revenue of $0.05 million during the quarter. Equities analysts forecast that Evaxion Biotech A/S will post -0.1 earnings per share for the current fiscal year.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.